[55]
Novopharm also asks the Court to note that
AB Hassle
, like the case at bar and every other case commenced under the
Regulations
, was commenced subsequent to the filing of an NOA. In contrast to Prothonotary Milczynski's conclusion concerning the effect of an NOA, the Federal Court of Appeal found that the confidential nature of the relationship between generic manufacturers and Health Canada was sufficient to support a protective order, notwithstanding the delivery of an NOA.